SCHEMBL4751174

SCHEMBL4751174

CC12CC3CC(C)(C1)CC(ON1C(=O)c4ccccc4C1=O)(C3)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 6/20 0.41
GPR84 Q9NQS5 1/20 0.38
KDM4E B2RXH2 5/20 0.38
MAPT P10636 5/20 0.38
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 4/20 0.38
HPGD P15428 3/20 0.38
F2 P00734 3/20 0.38
MEN1 O00255 2/20 0.38
XBP1 P17861 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HTT P42858 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
VDR P11473 2/20 0.37
TSHR P16473 2/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31668593 0.80 GAA (0.40) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL12904736 0.80 GAA (0.40) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL2557909 0.77 EPHX2 (0.56) EPHX2KDM4EKMT2AALDH1A1HPGD
SCHEMBL4751176 0.68 GPR84 (0.37) EPHX2GPR84KDM4EMAPTKMT2A
SCHEMBL31588015 0.66 GAA (0.42) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL10441919 0.66 GAA (0.42) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL3162219 0.65 GRIN1 (0.42) EPHX2MAPTKMT2AMEN1NPSR1
SCHEMBL10441587 0.65 LMNA (0.42) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL10441985 0.65 LMNA (0.42) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL8124150 0.65 HDAC6 (0.42) EPHX2KMT2AMEN1GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008135041-A1 ADAMANTYLOXYAMINE DERIVATIVES AND RELATED COMPOUNDS FOR USE AS NMDA AND/OR DPP-4 MODULATORS FOR THE THERAPY OF CNS DISEASES AND DIABETES SCHEBO BIOTECH AG (DE) 2008-11-13 WO disclosed